Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer IndicationsElena Ardini, Arturo Galvani, Maria Menichincheri et al.|Molecular Cancer Therapeutics|2016Cited by 317
Abstract A243: Characterization of NMS-E628, a small molecule inhibitor of anaplastic lymphoma kinase with antitumor efficacy in ALK-dependent lymphoma and non-small cell lung cancer modelsElena Ardini, Arturo Galvani, Micaela Russo et al.|Molecular Cancer Therapeutics|2009Cited by 31
Abstract A232: In vitro and in vivo activity of NMS-E628 against ALK mutations resistant to Xalkori.Elena Ardini, Arturo Galvani, Maria Menichincheri et al.|Molecular Cancer Therapeutics|2011Cited by 20
In vitro and in vivo activity of NMS-E628 against ALK mutations resistant to Xalkori.Elena Ardini, Arturo Galvani, Maria Menichincheri et al.|Unknown|2011Cited by 11
Abstract 2092: The ALK inhibitor NMS-E628 also potently inhibits ROS1 and induces tumor regression in ROS-driven models .Elena Ardini, Arturo Galvani, Maria Menichincheri et al.|Cancer Research|2013Cited by 10